References

Antitumour anthracyclines: progress and perspectives

10.1002/cmdc.202000131 · 2020 · External reference

Unresolved reference

External reference

Molecular mechanisms of anthracycline cardiovascular toxicity

10.1042/cs20200301 · 2021 · External reference

Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities

10.1016/j.jacc.2014.06.1167 · 2014 · External reference

Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?

10.1016/j.ejca.2023.02.019 · 2023 · External reference

Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1

10.1016/j.jacc.2017.09.1096 · 2017 · External reference

Cardiovascular disease and breast cancer: where these entities intersect

10.1161/cir.0000000000000556 · 2018 · External reference

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

10.1093/annonc/mdh097 · 2004 · External reference

Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer

10.1200/jco.2001.19.5.1444 · 2001 · External reference

A real-world analysis of FDA adverse event reporting system (FAERS) events for liposomal and conventional doxorubicins

10.1038/s41598-024-55185-4 · 2024 · External reference

Preclinical toxicity of liposome-incorporated annamycin: selective bone marrow toxicity with lack of cardiotoxicity

1995 · External reference

Comparison of annamycin to adriamycin in cardiac and MDR tumor cell systems

1999 · External reference

Effect of vesicle size and lipid composition on the in vivo tumor selectivity and toxicity of the non-cross-resistant anthracycline annamycin incorporated in liposomes

10.1002/ijc.2910610513 · 1995 · External reference

Annamycin, a non-cardiotoxic anthracycline demonstrates unique organotropism and activity against Ara-C and Venetoclax resistant AML

10.1182/blood-2024-206164 · 2024 · External reference

Preliminary results from a phase 1/2 study of liposomal annamycin (L-ANN) in combination with cytarabin for the treatment of patients with acute myeloid leukemia (AML) that is refractory to or relapsed (r/r) after induction therapy

10.1182/blood-2023-184493 · 2023 · External reference